208 related articles for article (PubMed ID: 23701201)
1. Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Vento S
AIDS Patient Care STDS; 2013 Jun; 27(6):315-6. PubMed ID: 23701201
[No Abstract] [Full Text] [Related]
2. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
4. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
[TBL] [Abstract][Full Text] [Related]
5. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.
Lanzafame M; Bonora S; Lattuada E; Calcagno A; Vento S
Braz J Infect Dis; 2011; 15(5):498-500. PubMed ID: 22230862
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
8. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
Ivanovic J; Bellagamba R; Nicastri E; Signore F; Vallone C; Tempestilli M; Tommasi C; Mazzitelli L; Narciso P
AIDS; 2010 Apr; 24(7):1083-4. PubMed ID: 20386380
[No Abstract] [Full Text] [Related]
9. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
[TBL] [Abstract][Full Text] [Related]
10. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
11. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
[No Abstract] [Full Text] [Related]
13. [Darunavir in treatment-naïve patients. The ARTEMIS study].
Estrada V; Fuster M
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
[TBL] [Abstract][Full Text] [Related]
14. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
15. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.
Arribas J; Pulido F; Hill A; Delft Yv; Moecklinghoff C
Int J STD AIDS; 2013 Aug; 24(8):679-81. PubMed ID: 24014249
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
18. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Nishijima T; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2012 Mar; 26(5):649-51. PubMed ID: 22233654
[TBL] [Abstract][Full Text] [Related]
20. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]